Primary regulatory
SUSTAIN-6: Semaglutide CV Outcomes in T2D: ClinicalTrials.gov
ClinicalTrials.gov registry for SUSTAIN-6, establishing CV safety of semaglutide in Type 2 diabetes.
ClinicalTrials.govPublished Nov 1, 2012Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- ClinicalTrials.gov
- Source type
- Primary regulatory
- Registry ID
clinicaltrials-gov-sustain6
Source usage
Linked from 3 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.